Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials

Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials

An increasing awareness of the disease, new diagnostic tools and novel therapeutic opportunities have dramatically changed the management of patients with amyloid transthyretin cardiomyopathy (ATTR-CM). Supportive therapies have shown limited benefits, mostly related to diuretics for the relief from...

Full description

Bibliographic Details
Main Authors:	Daniela Tomasoni, Giovanni Battista Bonfioli, Alberto Aimo, Marianna Adamo, Marco Canepa, Riccardo M. Inciardi, Carlo Mario Lombardi, Matilde Nardi, Matteo Pagnesi, Mauro Riccardi, Giuseppe Vergaro, Enrico Vizzardi, Michele Emdin, Marco Metra
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Series:	Frontiers in Cardiovascular Medicine
Subjects:	transthyretin cardiac amyloidosis (ATTR-CA) treatment tafamidis siRNA antisense oligonucleotide gene editing
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2023.1154594/full

Similar Items

Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy
by: Paolo Morfino, et al.
Published: (2023-04-01)

Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysisResearch in context
by: Jie Wang, et al.
Published: (2023-09-01)

Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin Amyloidosis
by: Luís Gales
Published: (2019-05-01)

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy
by: Nicholas Streicher, et al.
Published: (2024-03-01)

The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism
by: Chiara Sanguinetti, et al.
Published: (2022-08-01)

Tafamidis medication adherence and persistence in patients with transthyretin amyloid cardiomyopathy in Japan
by: Takao Kato, et al.
Published: (2024-10-01)

Specific therapeutic options for transthyretin amyloidosis
by: Zoltán Pozsonyi
Published: (2024-12-01)

Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient
by: Giuseppe Vergaro, MD, PhD, et al.
Published: (2021-03-01)

Outcomes in Cardiac Transthyretin Amyloidosis and Association With New York Heart Association Class: Real‐World Data
by: Maximilian Leo Müller, et al.
Published: (2024-07-01)

SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin
by: Stephan Dobner, et al.
Published: (2023-02-01)

Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis
by: Hiroaki Matsushita, et al.
Published: (2022-06-01)

Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)
by: Sepideh Attal, et al.
Published: (2024-04-01)

Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study
by: Taha N. Qarni, et al.
Published: (2024-05-01)

Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild‐type transthyretin amyloid cardiomyopathy
by: Seiji Takashio, et al.
Published: (2023-08-01)

Tafamidis therapy in transthyretin amyloid cardiomyopathy: a narrative review from clinical trials and real-world evidence
by: Ikponmwosa Jude Ogieuhi, et al.
Published: (2024-07-01)

The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement
by: Chafic Karam, et al.
Published: (2024-11-01)

Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report
by: Hiroyuki Yamamoto, et al.
Published: (2018-12-01)

Advances in the treatment of hereditary transthyretin amyloidosis: A review
by: Morie A. Gertz, et al.
Published: (2019-09-01)

Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy
by: Falcão de Campos C, et al.
Published: (2023-02-01)

Phenotypic heterogeneity and diagnostic features of transthyretin amyloidosis with polyneuropathy
by: S. S. Nikitin, et al.
Published: (2021-12-01)

Oligomerization Profile of Human Transthyretin Variants with Distinct Amyloidogenicity
by: Ana Frangolho, et al.
Published: (2020-12-01)

Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years
by: Giampaolo Merlini, et al.
Published: (2020-02-01)

A Clinical Case of the Hereditary Transthyretin Amyloidosis
by: E. V. Reznik, et al.
Published: (2021-05-01)

The application of biomarkers in hereditary transthyretin amyloidosis – an ongoing research project on bulgarian patients
by: Z. Pavlova, et al.
Published: (2024-04-01)

Chest pain in a patient with transthyretin cardiac amyloidosis: A case report
by: Linfeng Xie, et al.
Published: (2024-04-01)

Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis
by: Alberto Aimo, MD, et al.
Published: (2020-07-01)

Transthyretin amyloid cardiomyopathy in France: A cross-sectional multi-centre study (333 patients)
by: Thibaud Damy, et al.
Published: (2024-01-01)

Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study
by: Cheng-Hsuan Tsai, et al.
Published: (2023-09-01)

Best Practices in Nuclear Imaging for the Diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in KSA: The Eagle Eyes of Local Experts
by: Abdullah Alqarni, et al.
Published: (2024-01-01)

Dapagliflozin treatment and cardiovascular outcome in RBP4/TTRVal30Met (transthyretin cardiac amyloidosis) mice
by: Zonglin Li, et al.
Published: (2024-02-01)

Biochemical and biophysical properties of a rare TTRA81V mutation causing mild transthyretin amyloid cardiomyopathy
by: Qiuyan Sha, et al.
Published: (2024-02-01)

Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm
by: Yoshiki Sekijima, et al.
Published: (2018-01-01)

Tissue Characterization in Cardiac Amyloidosis
by: Veronica Musetti, et al.
Published: (2022-11-01)

A clinical case of transthyretin amyloidosis with manifestations of seronegative arthritis
by: V. A. Mareeva, et al.
Published: (2024-02-01)

Health‐related quality of life among transthyretin amyloid cardiomyopathy patients
by: Per Eldhagen, et al.
Published: (2023-06-01)

Safety, Tolerability, and Outcomes of Tafamidis for the Treatment of Acquired Amyloid Neuropathy in Domino Liver Transplant Recipients
by: Velina Nedkova-Hristova, et al.
Published: (2024-05-01)

Myocardial work assessment to improve baseline risk stratification in patients with transthyretin amyloidosis
by: Ana Moya, et al.
Published: (2024-12-01)

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
by: Dulce Brito (Chair), et al.
Published: (2023-10-01)

Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data
by: Nicholas J. Viney, et al.
Published: (2021-02-01)

Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond
by: Paolo Morfino, et al.
Published: (2022-08-01)